Opus Genetics, Inc. Earnings

The next earnings date for Opus Genetics, Inc. is August 11, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Opus Genetics, Inc. Earnings

Report Date	Estimated Earnings Per Share
08/11/2026	$-0.17

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Opus Genetics, Inc. Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/12/2026	Before Market	$-0.75	-421.20%
03/10/2026	Before Market	$-0.29	-146.81%
11/12/2025	Before Market	$-0.25	-90.40%
08/13/2025	After Market	$-0.12	42.06%
05/15/2025	After Market	$-0.24	4.95%
03/31/2025	Before Market	$-0.22	15.12%
11/12/2024	Before Market	$-0.29	-20.88%
08/13/2024	Before Market	$-0.30	-16.46%
05/10/2024	Before Market	$-0.29	-114.34%
03/08/2024	Before Market	$-0.21	-296.23%
11/13/2023	Before Market	$0.25	211.51%
08/11/2023	Before Market	$-0.24	-5.12%
05/15/2023	Before Market	$-0.28	-80.06%
03/30/2023	Before Market	$1.58	61.69%
11/04/2022	After Market	$-0.22	24.45%
08/12/2022	Before Market	$-0.25	25.44%
05/13/2022	Before Market	$-0.35	0.99%
03/24/2022	Before Market	$-0.35	-20.90%
11/12/2021	Before Market	$-0.25	30.86%
08/12/2021	Before Market	$-0.52	-41.69%
05/07/2021	Before Market	$-0.47	34.69%
03/10/2021	After Market	$-5.18	-1,121.12%
10/29/2020	Before Market	---	---
08/14/2020	Before Market	---	---
05/07/2020	Before Market	---	---
02/21/2020	Before Market	---	---
11/06/2019	After Market	$-1.96	10.16%
08/07/2019	Before Market	$-2.44	29.22%
05/10/2019	After Market	$-2.48	34.23%
03/07/2019	After Market	$-4.32	31.45%
11/02/2018	After Market	$-8.16	0.99%
08/03/2018	After Market	$-5.76	34.90%
05/04/2018	After Market	$-3.36	50.50%
03/09/2018	After Market	$-4.32	34.80%
11/03/2017	Before Market	$-1.92	81.44%
08/04/2017	After Market	$1.44	114.14%
05/04/2017	Before Market	$-9.60	-18.79%
02/24/2017	After Market	$4.80	139.60%
11/04/2016	After Market	$-4.80	50.50%
08/08/2016	Before Market	$-4.80	50.50%
05/09/2016	Before Market	$-9.60	0.99%
03/14/2016	After Market	$-9.60	20.79%
11/02/2015	After Market	$-9.60	40.59%
08/07/2015	After Market	$-9.60	25.75%
05/08/2015	After Market	$-9.60	25.75%
03/17/2015	Before Market	$-9.60	0.99%
11/12/2014	After Market	$-4.80	57.56%
08/13/2014	---	$0	100.00%
05/14/2014	---	$-43.20	-345.54%
03/21/2014	---	$-4.80	67.00%
11/14/2013	Before Market	$-9.60	-32.01%
05/09/2013	---	$-4.80	50.50%
03/22/2013	After Market	$0	100.00%
03/16/2012	Before Market	$4.80	124.75%
11/09/2011	---	$-4.80	87.62%
08/09/2011	After Market	$-28.80	0.99%
05/09/2011	After Market	$-24	-23.76%
03/16/2011	After Market	$-14.40	0.99%
03/31/2010	After Market	$-9.60	33.99%
11/16/2009	After Market	$-9.60	33.99%

More About Opus Genetics, Inc.

Website

https://opusgtx.com

Country

USA

Full Time Employees

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

“Opus Genetics, Inc. Earnings” Can Refer to the Opus Genetics, Inc. Earnings Date

Some people say “Opus Genetics, Inc. earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Opus Genetics, Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Opus Genetics, Inc. Stock on the Earnings Date

If you own Opus Genetics, Inc. stock (IRD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Opus Genetics, Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Opus Genetics, Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Opus Genetics, Inc. Earnings

You can contact us any time if you would like to ask questions about Opus Genetics, Inc. earnings or anything else related to the stock market.